Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

An Open-Label, Phase 1 Study to Characterize the Effects of a Strong Cytochrome P450 3A4 Inducer on the Pharmacokinetics of Bomedemstat in Healthy Adult Participants

Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases.

The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedemstat in the body when it is given alone and after multiple doses of another medicine called carbamazepine (CBZ).

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months before entering the study.
• Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m^2
• Medically healthy with no clinically significant medical history

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• History or presence of any of the following:

  • Seizures
  • Negative reactions in the blood system to any drugs
  • Depression, unusual changes in mood or behavior or suicidal thoughts or behavior

• History of cancer

• Regular user of cannabis products within 6 months before entering the study.

• Unable to stop using or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days before entering the study.